Daniel C. Adelman

2019 - Aimmune Therapeutics

In 2019, Daniel C. Adelman earned a total compensation of $1.9M as Chief Medical Officer at Aimmune Therapeutics, a 10% decrease compared to previous year.

Compensation breakdown

Bonus$4,279
Non-Equity Incentive Plan$179,706
Option Awards$1,007,504
Salary$445,700
Stock Awards$281,675
Other$2,000
Total$1,920,864

Adelman received $1M in option awards, accounting for 52% of the total pay in 2019.

Adelman also received $4.3K in bonus, $179.7K in non-equity incentive plan, $445.7K in salary, $281.7K in stock awards and $2K in other compensation.

Rankings

In 2019, Daniel C. Adelman's compensation ranked 6,152nd out of 13,971 executives tracked by ExecPay. In other words, Adelman earned more than 56.0% of executives.

ClassificationRankingPercentile
All
6,152
out of 13,971
56th
Division
Manufacturing
2,309
out of 5,701
60th
Major group
Chemicals And Allied Products
839
out of 2,200
62nd
Industry group
Drugs
707
out of 1,886
63rd
Industry
Pharmaceutical Preparations
522
out of 1,398
63rd
Source: SEC filing on April 9, 2020.

Adelman's colleagues

We found four more compensation records of executives who worked with Daniel C. Adelman at Aimmune Therapeutics in 2019.

2019

Jayson Dallas

Aimmune Therapeutics

Chief Executive Officer

2019

Andrew Oxtoby

Aimmune Therapeutics

Chief Commercial Officer

2019

Eric Bjerkholt

Aimmune Therapeutics

Chief Financial Officer

2019

Douglas Sheehy

Aimmune Therapeutics

General Counsel

News

In-depth

You may also like